Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Hansa Biopharma AB (publ)    HNSA   SE0002148817

HANSA BIOPHARMA AB (PUBL)

(HNSA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.
Sales per Business
20182019Delta
SEK (in Million)%SEK (in Million)%
Royalty and Licensing2.0761.7%2.2767.3% +9.37%
Milestone0.62118.5%0.57317% -7.73%
Patent Reimbursement0.66619.8%0.52615.6% -21.02%
Sales per region
20182019Delta
SEK (in Million)%SEK (in Million)%
Sweden3.36100%3.36100% +0.18%
Managers and Directors
NameAgeSinceTitle
Søren Tulstrup552018President & Chief Executive Officer
Ulf Arne Wiinberg612018Chairman
Christian Kjellman, Dr.532008Chief Operating & Scientific Officer
Donato Spota-2019Chief Financial Officer
Achim Kaufhold, Dr.622020Chief Medical Officer
Birgit Stattin Norinder722016Independent Director
Anders Gersel Pedersen, Dr.692018Independent Director
Andreas Eggert532018Independent Director
Eva Nilsagård562019Director
Mats Blom542019Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 44,473,452 44,028,717 99.0% 0 0.0% 95.9%
Stock B 0 1,421,457 0 0.0% 1,421,457 100.0%
Shareholders
NameEquities%
Redmile Group LLC 4,625,590 10.4%
Consonance Capital Management LP 2,212,527 4.97%
Bengt Ågerup 2,155,379 4.85%
Invesco Advisers, Inc. 1,999,188 4.50%
Handelsbanken Fonder AB 1,949,889 4.38%
Thomas Olausson 1,750,474 3.94%
Tredje AP-fonden 1,316,470 2.96%
Fjärde AP-fonden 1,112,044 2.50%
Max Mitteregger Kapitalförvaltning AB 1,025,000 2.30%
ClearBridge LLC 1,012,786 2.28%
Holdings
NameEquities%Valuation
Hansa Medical AB 1,421,457100.0%41,747,026 USD
Company contact information
Hansa Biopharma AB
Scheelevägen 22
Lund, Skane 223 63

Phone : +46.46.16.56.70
Fax : +46.46.12.77.75
Web : http://www.hansamedical.com